HA
AVDL

Heartland Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

Heartland Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-700,000
Closed -$7.35M – 197
2017
Q3 		$7.35M Hold
700,000
– – 0.48% 106
2017
Q2 		$7.72M Hold
700,000
– – 0.5% 96
2017
Q1 		$6.78M Buy
700,000
+187,617
+37% +$1.88M 0.41% 117
2016
Q4 		$5.32M Buy
512,383
+112,383
+28% +$1.23M 0.29% 134
2016
Q3 		$4.96M Buy
400,000
+38,955
+11% +$509K 0.28% 130
2016
Q2 		$3.88M Sell
361,045
-138,955
-28% -$1.48M 0.22% 149
2016
Q1 		$5.52M Buy
500,000
+250,000
+100% +$2.48M 0.29% 129
2015
Q4 		$3.05M Buy
+250,000
New +$3.9M 0.12% 162

Other funds holding AVDL

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Heartland Advisors's AVDL Position: Q4 2017 in Review

Heartland Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q4 2017, closing a stake of 700,000 shares — an estimated $7.35M sold.

Heartland Advisors first reported a position in AVDL in Q4 2015 and held it in 8 quarters. The position peaked at $7.72M in Q2 2017. 83 funds tracked by Wall St. Rank hold AVDL as of Q4 2017.

  • Heartland Advisors reported no remaining Avadel Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Heartland Advisors sold 700,000 Avadel Pharmaceuticals shares in Q4 2017, an estimated $7.35M.
  • Heartland Advisors first reported a position in Avadel Pharmaceuticals in Q4 2015 and held it in 8 quarters.
  • Heartland Advisors's Avadel Pharmaceuticals position peaked at $7.72M in Q2 2017.
  • 83 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2017.

Based on Heartland Advisors's 13F filing for Q4 2017, filed 2 Feb 2018.